Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin'...(ncements and insights in thetreatment of...),Health

Date:6/5/2008

ncements and insights in the treatment of malignant lymphomas," said Dr. Michael J. Keating, University of Texas MD Anderson Cancer Center professor of medicine, internist for the department of hematology, ICML advisory board member and a member of Micromet's BiTE Antibody Scientific Advisory Board. "The data on blinatumomab show that it holds the promise to become an effective therapy for a number of lymphomas and leukemias."

(1) Bargou R. et al. (2008). Anti-CD19 BiTE Antibody MT103 (MEDI-538)

Induces Durable Objective Responses in Patients with Relapsed

Non-Hodgkin's Lymphoma (NHL). Update from Ongoing Phase I Study

MT103-104. ICML, Lugano, 2008.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lympho
'/>"/>

SOURCE Micromet, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
2. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
5. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research